Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
  • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
  • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods

Definitions

• This invention is related to film coated tablets and orally disintegrating formulations which are used in the treatment of respiratory tract infections and comprise cefditoren pivoxil with improved stability.
• Cefditoren pivoxil is a third generation cephalosporin which is used in the treatment of respiratory tract infections (Formula I).
• Cefditoren pivoxil film coated tablets are present in the market in the form of 200 mg and 400 mg oral dosage forms. Additionally, its 30 mg/0.3 g and 50 mg/0.5 g sachet forms are also available for pediatric usage.
• Cefditoren pivoxil is first disclosed in patent application EP175610 A2 (US4839350). It has a wide antimicrobial spectrum and low toxicity when used orally. In related patents, the effectiveness of cefditoren pivoxil in the treatment infectious diseases caused by gram positive and negative bacteria is disclosed.
• Cefditoren pivoxil freely dissolves in diluted hydrochloric acid. It is sparingly soluble in methanol, slightly soluble in acetonitrile and ethanol (95%), slightly soluble in diethylether and practically insoluble in water (less than 0.1mg/ml).
• EP0629404 A1 (Meiji Seika Pharma) is about a formulation using hydroxypropylcellulose to increase the wettability and solubility of Cefditoren pivoxil.
• US5958915 (Meiji Seika Pharma) is related to Cefditoren pivoxil tablet formulation whose bitter taste is repressed and solubility in water and absorption is increased.
• the characteristic of the patent is that the formulation comprises water soluble casein salt (sodium and potassium caseinate).
• EP 1389462 (Meiji Seika Pharma) is related to obtaining amorphous cefditoren pivoxil by grinding the cefditoren pivoxil in crystal form with organic polymer.
• EP1671635B1 and EP1555024B1 are related to suspension formulations which contain sucrose fatty acid ester (DK Ester SS).
• WO 99/34832 (Meiji Seika Pharma) is related to cephalosporin compositions with crystallographic stability and production methods thereof. It is related to formulations which provide the desired values in the dissolution of end product with the addition of water soluble and orally administrable polymer to the composition containing the amorphous form of cefditoren pivoxil.
• WO 98/12200 (Meiji Seika Pharma) is related to formulations comprising cefditoren pivoxil in crystal form with high purity and thermal stability and also to the production processes with a first step of converting amorphous cefditoren pivoxil into crystal form.
• Cefditoren pivoxil molecule decays under heat, light, basic, acidic and oxidative conditions. Additionally, its impurity profile contains many known impurities. Its vulnerability to environmental conditions adversely affects the stability of end products containing cefditoren pivoxil. Therefore, compositions comprising cefditoren pivoxil with impurity profiles at an acceptable level are still needed.
• the present invention is related to the stable pharmaceutical formulations comprising orally administered cefditoren pivoxil and the preparation of said formulations.
• Cefditoren pivoxil present in the pharmaceutical formulations according to present invention may be in the form of its pharmaceutically acceptable salts, hydrates, solvates, esters, enantiomers, diastereomers or combinations thereof and may be in the form crystal, amorphous or combinations thereof in terms of polymorphic structure.
• compositions may contain stabilizers in order to prevent the degradation of active substance and to provide a longer shelf life.
• stabilizer excipients such as antioxidants, chelating compounds, photo-protective compounds, antimicrobial preservative agents may be used.
• antioxidant agents used in pharmaceutical formulations are substances such as ascorbyl palmitate, ascorbic acid, butyl hydroxyanisol, butyl hydroxytoluen, potassium metabisulphite, sodium metabisulphite, propyl gallate and vitamin E.
• the inventors have found out that the impurity profiles of formulations comprising cefditoren pivoxil were improved when they contain Vitamin E as antioxidant.
• the present invention is related to cefditoren pivoxil formulations comprising vitamin E alone as antioxidant or vitamin E in combination with another antioxidant.
• Vitamin E is soluble in fat.
• the most effective tocopherol compound showing the effects of vitamin E is a-tocopherol.
• the present invention is related to film coated tablets and orally disintegrating formulations which comprise vitamin E in an amount of 0.1-1.0%, preferably 0.1-0.5%, and more preferably 0.3% by the total weight of tablet.
• compositions according to this invention are solid pharmaceutical formulations such as tablet, film coated tablet, dragee, orally disintegrating tablet, enteric tablet, modified release tablet. It is preferred that the solid pharmaceutical formulations are film coated tablet or orally disintegrating tablet.
• the pharmaceutical formulations according to invention also comprise at least one pharmaceutically acceptable excipient selected from the group composed of filling agent, disintegrant, surfactant, stabilizer and lubricant.
• the filling agent which may be used in the pharmaceutical forms according to the invention may be selected from the group comprising calcium carbonate, dibasic calcium phosphate, microcrystalline cellulose, dextrose, fructose, lactitol, lactose, magnesium carbonate, maltose, mannitol, sorbitol, sodium caseinate, potassium caseinate, calcium caseinate.
• the disintegrant which may be used in the pharmaceutical forms according to the invention may be selected from the group comprising carboxymethyl cellulose, carboxymethyl cellulose calcium, carboxymethyl cellulose sodium, croscarmellose sodium, crospovidone, hydroxypropyl cellulose, microcrystalline cellulose, methyl cellulose, starch, sodium starch glycolate.
• the surfactant which may be used in the pharmaceutical forms according to the invention may be selected among sodium lauryl sulphate, sodium tripolyphosphate, polysorbate, polyoxyethylene, polyoxypropylene glycol and similar agents.
• the lubricant which may be used in the pharmaceutical forms according to the invention may be selected from the group comprising talc, magnesium stearate, PEG 6000, silicone dioxide, sodium benzoate, potassium benzoate, stearic acid, sodium stearyl fumarate and/or a combination thereof.
• Aromatic agent according to the invention may be selected among peppermint, menthol, methyl salicylate, eucalyptol, cinnamon, 1 -methyl acetate, sage, eugenol, oxanone, lemon, orange, strawberry, banana, blackberry, fruit mixture or mixture thereof.
• Sweetener according to the invention may be selected from the group comprising acesulfame potassium, aspartame, fructose, maltitol, xylitol, saccharine, sodium cyclamate, sucraiose and sucrose.
• Core tablets according to the invention may be coated with coating compositions comprising film coating agents, for example sugar based coating agents, water soluble film coating agents, enteric coating agents, coating agents prepared to provide various release features (fast release, slow release, controlled release etc.) or any combination thereof.
• film coating agents for example sugar based coating agents, water soluble film coating agents, enteric coating agents, coating agents prepared to provide various release features (fast release, slow release, controlled release etc.) or any combination thereof.
• Water soluble film coating agents may be selected among cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyl cellulose and sodium carboxymethyl cellulose, synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pulluan or combinations thereof.
• cellulose derivatives such as hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, methyl hydroxyl cellulose and sodium carboxymethyl cellulose
• synthetic polymers such as polyvinyl acetal diethyl aminoacetate, aminoalkyl methacrylate copolymers and polyvinylpyrrolidone and polysaccharides such as pulluan or combinations thereof.
• saccharose may be used alone or optionally in combination with one of the agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatin, gum Arabic, polyvinylpyrrolidone and pulluan or any combination thereof.
• agents such as talc, calcium carbonate, calcium phosphate, calcium sulphate, gelatin, gum Arabic, polyvinylpyrrolidone and pulluan or any combination thereof.
• Film coated tablet formulations comprise 200 mg or 400 mg cefditoren pivoxil and excipients with the amounts (by total tablet weight) given below:
• At least one disintegrant 35% to 45% by weight
• At least one surfactant 5% to 10% by weight
• At least one stabilizer 0.1% to 1% by weight
• At least one lubricant 0.1% to 1% by weight.
• Disintegrating tablet formulations comprise 30 mg or 50 mg cefditoren pivoxil and excipients with the amounts (by total tablet weight) given below: At least one filling agent 30% to 40% by weight,
• At least one disintegrant 20% to 30% by weight At least one disintegrant 20% to 30% by weight
• At least one surfactant 1% to 5% by weight
• At least one stabilizer 0.1% to 1% by weight
• At least one aromatic agent 1% to 10% by weight
• At least one sweetener 1% to 8% by weight
• At least one glidant 0.1% to 1% by weight
• At least one lubricant 0.1% to 1% by weight
• the pharmaceutical formulation according to the invention with appropriate stability and desired solubility values may be used in the treatment infectious diseases caused by gram positive and negative bacteria.
• Film coated dosage forms are represented in Table 1. Core tablets contain about 43.8 % cefditoren pivoxil.
• Test formulations are manufactured by the process below.
• Vitamin E is dissolved in ethanol.
• Cefditoren pivoxil, sodium caseinate and croscarmellose sodium are placed in HSM and mixed. 4. Sodium tripolyphosphate and vitamin E solutions are added onto the mixture in HSM successively and wet granulation is carried out.
• the granules are dried at 50°C in oven, until the drying loss reaches 3 % (maximum).
• Test formulations are manufactured by the process below.
• Vitamin E is dissolved in ethanol.
• Cefditoren pivoxil, sodium caseinate and croscarmellose sodium are placed in HSM and mixed. 4. Sodium tripolyphosphate and vitamin E solutions are added onto the mixture in HSM successively and wet granulation is carried out.
• the granules are dried at 50°C in oven, until the drying loss reaches 3 % (maximum).
• Crospovidone, aspartam, acesulfame K, aerosol 200, strawberry aroma banana aroma are added to the mannitol SD 200 present in the outer phase and mixed.
• test formulations and reference products have similar dissolution results and since their solubility in a dissolution medium having pH 1.2 is higher than 85% after 15 minutes, they are accepted as consistent according to CPMP/QWP/EWP/1401/98 without need for f 2 calculation.
• test formulations 400mg film coated tablet and 50mg orally disintegrating tablet
• reference product 400mg tablet, Spectracef
• one generic product 200mg tablet, Cefiten
• Figure 1 The dissolution profiles of original product and 400 mg film coated tablet formulation in stomach medium without enzyme.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=52684635

Family Applications (1)

Country Status (2)

Families Citing this family (2)

Family Cites Families (9)

• 2015
  • 2015-01-16 EP EP15710289.8A patent/EP3244879A1/de not_active Withdrawn
  • 2015-01-16 WO PCT/TR2015/000016 patent/WO2016114727A1/en active Application Filing

Also Published As

Similar Documents

Legal Events